TRVX.OL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (25 May 2023 @ 22:09):

Stats
今日成交量	570 454
平均成交量	865 124
市值	123.47M
EPS	NOK0 ( 2024-02-15 )
下一个收益日期	( NOK0 ) 2024-05-09
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.294
ATR14	NOK0.0540 (9.94%)

音量相关性

長: 0.05 (neutral)

短: -0.83 (strong negative)

Signal:(37.845) Neutral

Targovax ASA 相关性

10 最正相关
ANDF.OL	0.969
EFUEL.OL	0.967
KMCP.OL	0.961
KOMPL.OL	0.957
ELIMP.OL	0.953
PLT.OL	0.948
NRC.OL	0.946
NOD.OL	0.943
VOW.OL	0.942
NEL.OL	0.941

10 最负相关
EIOF.OL	-0.95
BORR.OL	-0.945
HAFNI.OL	-0.933
WWI.OL	-0.926
VAR.OL	-0.912
SNI.OL	-0.905
NKR.OL	-0.905
FROY.OL	-0.905
KAHOT.OL	-0.899
EQNR.OL	-0.898

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Targovax ASA 相关性 - 货币/商品

0.87
( strong )

0.92
( very strong )

0.00
( neutral )

0.86
( strong )

0.11
( neutral )

-0.92
( very strong negative )

Targovax ASA 财务报表

Annual	2022
营收:	NOK10.00M
毛利润:	NOK10.00M (100.00 %)
EPS:	NOK-2.30

FY	2022
营收:	NOK10.00M
毛利润:	NOK10.00M (100.00 %)
EPS:	NOK-2.30

FY	2021
营收:	NOK0.00
毛利润:	NOK0.00 (0.00 %)
EPS:	NOK-1.271

FY	2020
营收:	NOK0.00
毛利润:	NOK0.00 (0.00 %)
EPS:	NOK-1.145

Financial Reports:

No articles found.

Targovax ASA

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.